I think if the topline data hits all 3 endpoints and as claimed RVX has a stable of molecules to follow for different indications, I see two things.

a) A bidding war among topline pharmas. If you look there are really not that many new drugs with new mechanisms and here we are talking about a mulititude of potential drugs with a new mechanism.

b) It would be a mistake for RVX to sell itself, it can easily keep on generating new molecules and licensing them. If even a few hit their target the royalties would be very significant.